Wearable Health Solutions (WHSI) 10-Q 20 Nov 23 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Sep. 30, 2023	Nov. 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	000-56368
Entity Registrant Name	WEARABLE HEALTH SOLUTIONS, INC.
Entity Central Index Key	0001443089
Entity Tax Identification Number	26-3534190
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2901 W. Coast Highway
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92663
City Area Code	917
Local Phone Number	541-5884
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,804,255,108

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Current Assets
Cash and cash equivalents	$ 10,658	$ 136,151
Accounts receivable, net	13,820	379
Inventory	8,555	8,555
Prepaid inventory	28,140	7,242
Total Current Assets	61,173	152,327
Property and equipment, net	35,402	38,689
Right-of-use assets	28,740	32,157
Total Assets	125,315	223,173
LIABILITIES AND SHAREHOLDERS' DEFICIT
COMMITMENTS AND CONTINGENCIES
Current Liabilities
Accounts payable	186,417	162,936
Accrued expenses and other current liabilities	494,764	517,067
Short-term lease liability	14,443	14,039
Related party debt, net	1,067,595	799,132
Deferred revenue	132,417	103,412
Line of credit	0	397,500
Notes payable	398,333	398,333
Notes payable - other	50,000	50,000
Notes payable - related party	170,000	170,000
Convertible notes Leonite, net	270,635	246,148
Convertible notes other	518,750	673,750
Stock subscription liability	249,500	249,500
Total Current Liabilities	3,552,854	3,781,817
Long-term lease liability	14,717	18,468
Total Liabilities	3,567,571	3,800,285
SHAREHOLDERS' DEFICIT
Common stock: $0.0001 par value; 3,000,000,000 shares authorized, 1,804,255,108 and 1,566,255,108 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively	180,425	156,625
Common stock to be issued 48,725,832 and 169,767,499 shares as of September 30, 2023 and June 30, 2023, respectively	216,289	604,335
Additional paid-in capital	37,952,848	37,472,648
Accumulated deficit	(41,792,947)	(41,811,849)
Total Shareholders' Deficit	(3,442,256)	(3,577,112)
Total Liabilities and Shareholders' Deficit	125,315	223,173
Series A Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	1	1
Series B Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	1	1
Series C Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	684	684
Series D Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	43	43
Series E Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	$ 400	$ 400

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,804,255,108	1,566,255,108
Common stock, shares outstanding	1,804,255,108	1,566,255,108
Common stock to be issued	48,725,832	169,767,499
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	688	688
Preferred stock, shares outstanding	688	688
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	62,500	62,500
Preferred stock, shares issued	9,938	9,938
Preferred stock, shares outstanding	9,938	9,938
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	6,944,445	6,944,445
Preferred stock, shares issued	6,838,889	6,838,889
Preferred stock, shares outstanding	6,838,889	6,838,889
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	425,000	425,000
Preferred stock, shares outstanding	425,000	425,000
Series E Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	4,000,000	4,000,000
Preferred stock, shares outstanding	4,000,000	4,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 142,412	$ 216,460
Cost of sales	(50,127)	(120,002)
Gross profit	92,285	96,458
Operating expenses
Selling expense	285	190,010
Depreciation	3,287	2,544
Research and development expense	15,200	2,180
Consulting and professional fees	125,185	42,314
Insurance	12,136	29,192
Rent	4,080	5,410
Salaries and wages	187,940	502,856
General and administrative	79,903	81,977
Total operating expenses	428,015	856,483
Loss from operations	(335,731)	(760,025)
Other income / (expense), net
Other income	0	19,500
Interest income	0	1,500
Gain on debt extinguishment	397,500	0
Interest expense	(42,867)	(9,742)
Total other income (expense), net	354,633	11,258
Net income (loss) before income taxes	18,902	(748,767)
Income taxes	0	0
Net income (loss)	$ 18,902	$ (748,767)
Net income (loss) per common share - Basic	$ 0	$ 0
Net income (loss) per common share - Diluted	$ 0	$ 0
Weighted average common shares outstanding - Basic	1,648,325,760	1,517,790,978
Weighted average common shares outstanding - Diluted	2,169,711,734	1,517,790,978

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Deficit (unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series B [Member]	Preferred Stock Series C [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 149,314	$ 407,677	$ 36,773,035	$ (39,423,382)	$ (2,092,227)
Beginning balance, shares at Jun. 30, 2022	688	9,938	6,838,889	425,000	4,000,000	1,493,142,608	35,602,500
Income for the period									(748,767)	(748,767)
Common stock for compensation						$ 500	$ (30,000)	65,500		36,000
Common stock for compensation, shares						5,000,000	(2,000,000)
Common stock to be issued for compensation							$ 441			441
Common stock to be issued for compensation, shares							32,500
Common stock for officer compensation						$ 695	$ (101,262)	100,567
Common stock for officer compensation, shares						6,950,000	(6,950,000)
Common stock to be issued for officer comp							$ 47,144			47,144
Common stock to be issued for officer comp, shares							3,475,000
Shares issued for services						$ 500		88,500		89,000
Shares issued for services, shares						5,000,000
Shares sold for cash - prior quarter						$ 2,150	$ (215,000)	212,850
Shares sold for cash - prior quarter, shares						21,500,000	(21,500,000)
Shares sold for cash - current quarter							$ 604,500			604,500
Shares sold for cash - current quarter, shares							67,950,000
Payment of subscription receivable								30,000		30,000
Ending balance, value at Sep. 30, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 153,159	$ 713,500	37,270,452	(40,172,149)	(2,033,909)
Ending balance, shares at Sep. 30, 2022	688	9,938	6,838,889	425,000	4,000,000	1,531,592,608	76,610,000
Beginning balance, value at Jun. 30, 2023	$ 1	$ 1	$ 684	$ 43	$ 400	$ 156,625	$ 604,335	37,472,648	(41,811,849)	(3,577,112)
Beginning balance, shares at Jun. 30, 2023	688	9,938	6,838,889	425,000	4,000,000	1,566,255,108	169,767,499
Income for the period									18,902	18,902
Common stock for officer compensation							$ 1,954			1,954
Common stock for officer compensation, shares							1,958,333
Shares sold for cash - prior quarter						$ 13,800	$ (405,000)	391,200
Shares sold for cash - prior quarter, shares						138,000,000	(138,000,000)
Shares sold for cash - current quarter						$ 10,000	$ 15,000	89,000		114,000
Shares sold for cash - current quarter, shares						100,000,000	15,000,000
Ending balance, value at Sep. 30, 2023	$ 1	$ 1	$ 684	$ 43	$ 400	$ 180,425	$ 216,289	$ 37,952,848	$ (41,792,947)	$ (3,442,256)
Ending balance, shares at Sep. 30, 2023	688	9,938	6,838,889	425,000	4,000,000	1,804,255,108	48,725,832

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flow from operating activities
Net income (loss)	$ 18,902	$ (748,767)
Adjustment for non-cash charges and other items:
Depreciation	3,287	2,544
Amortization of deferred debt issuance costs	11,987	172,585
Amortization of debt discount	12,500	0
Stock-based compensation expense	1,954	0
Gain on debt extinguishment	(397,500)	0
Total adjustments	(348,870)	(573,638)
Changes in working capital
Decrease / (increase) in accounts receivables	(13,441)	(16,657)
Decrease / (increase) in inventory	0	(34,132)
Decrease / (increase) in prepaid inventory	(20,898)	43,518
Decrease / (increase) in prepaid expenses	0	(1,325)
(Decrease) / increase in trade and other payables	23,481	8,357
(Decrease) / increase in accrued expenses	(22,233)	15,765
(Decrease) / increase in accrued expenses - related party	178,254	0
(Decrease) / increase in deferred revenue	29,004	(3,000)
Total changes in working capital	174,167	12,526
Cash flow used in operating activities	(174,703)	(561,112)
Cash flow used in investing activities
Purchase of property, plant & equipment	0	(9,442)
Cash flow used in investing activities	0	(9,442)
Cash flow provided by financing activities
Proceeds received from related parties	90,210	134,835
Repayments of note payable	(155,000)	(13,382)
Proceeds from issuance of stock (net of subscriptions receivable) and stock subscription liability	114,000	634,500
Cash flow from financing activities	49,210	755,953
Increase/(decrease) in cash and cash equivalents	(125,493)	185,399
Cash and cash equivalents at beginning of the period	136,151	70,505
Cash and cash equivalents at end of the period	10,658	255,904
Cash paid during the periods for:
Interest	0	0
Taxes	$ 0	$ 0

Nature and Continuance of Opera

Nature and Continuance of Operations	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature and Continuance of Operations	Note 1 – Nature and Continuance of Operations Wearable Healthcare Solutions Inc. (the Company) was incorporated as Medical Alarm Concepts Holding, Inc. on June 4, 2008, under the laws of the State of Nevada. The Company was formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability company (“Medical LLC”). On May 26, 2016, the Company filed an Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change its name from “Medical Alarm Concepts, Inc.” to “Wearable Health Solutions, Inc.” The Company provides mobile health (mHealth) products and services to be used by customers in case of an emergency. As a provider of personal emergency devices, the Company provides innovative wearable healthcare products, tracking services, and turn-key solutions that enable our users to be proactive with their health, as well as safe and protected. The Company’s flagship products are the iHelp devices, the 3G and the next generation iHelp MAX™ – personal emergency alarm that are used to summon help in the event of an emergency at home. Basis of presentation The accompanying interim consolidated financial statements are unaudited, but in the opinion of management of Wearable Healthcare Solutions, Inc. (the Company), contain all adjustments, which include normal recurring adjustments, necessary to present fairly the financial position at September 30, 2023, and the results of operations and changes in shareholders’ deficit for the three months ended September 30, 2023 and cash flows for the three months ended September 30, 2023. The balance sheet as of June 30, 2023, is derived from the Company’s audited financial statements. These unaudited condensed financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations, and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America, or GAAP. These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended June 30, 2023 and 2022, which are included in the Company’s June 30, 2023 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission on October 20, 2023. Certain information and footnote disclosures normally included in financial statements that have been prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, although management of the Company believes that the disclosures contained in these financial statements are adequate to make the information presented therein not misleading. For further information, refer to the financial statements and the notes thereto included in the Company’s Annual Report on this Form 10-K for the fiscal year ended June 30, 2023. The results of operations for the three months ended September 30, 2023, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending June 30, 2024.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Principles of Consolidation Use of Estimates Cash and Cash Equivalents Accounts Receivable 13,820 379 23,705 23,705 Software Development for internal use 50,000 5 Concentration of Credit Risk Recognition of Revenues Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company recognizes revenue when it is realized or realizable and earned. For hardware sales, the Company recognizes revenues at a point in time when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues over the term of the service contract and when the services are rendered. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues, and records the balance of revenues as they become current. Schedule of revenues Three Months Ended 2023 2022 Revenue Hardware revenue $ 25,755 $ 26,876 Service Revenue 116,657 189,584 Total Revenue $ 142,412 $ 216,460 Deferred revenues at September 30, 2023 and June 30, 2023 was $ 132,417 103,412 Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2023, 2022, and 2021 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed. Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards. Research and Development 15,200 2,180 Basic and Diluted Loss per Common Share - Schedule of anti-dilutive shares September 30, Shares Outstanding Dilution 2023 2022 Series A convertible preferred stock 688 1 share A: 2 shares 1,376 1,376 Series B convertible preferred stock 9,938 1 share B: 2 shares 19,876 19,876 Series C convertible preferred stock 6,838,889 1 share C: 10 shares 68,388,890 68,388,890 Series D convertible preferred stock 425,000 1 share D: 10 shares 4,250,000 4,250,000 Series E convertible preferred stock 4,000,000 1 share E: 100 shares 400,000,000 400,000,000 Common stock to be Issued Leonite Convertible notes 15,000,000 1:1 15,000,000 – Stock subscription liability 24,950,000 1:1 24,950,000 – Others 8,775,832 1:1 8,775,832 76,610,000 Total potentially dilutive shares 521,385,974 549,270,142 Reconciliation of earnings per share Three Months ended 2023 2022 Numerator: Net Income (loss) $ 18,902 $ (748,767 ) Denominator: Weighted average common shares outstanding - basic 1,648,325,760 1,517,790,978 Weighted average common shares outstanding - diluted 2,169,711,734 1,517,790,978 Net income (loss) per share - basic $ 0.00 $ (0.00 ) Net income (loss) per share - diluted $ 0.00 $ (0.00 ) The Company has recognized income for this quarter, as a result, the basic and diluted share bases will not be presented as the same. For the three month periods ended September 30, 2023 and 2022, the Company recognized income of $0.00 and incurred losses of ($0.00) per basic share, respectively. For the three month periods ended September 30, 2023 and 2022, the Company recognized income of $0.00 and incurred losses ($0.00) per diluted share, respectively. Recent Accounting Pronouncements The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Going Concern

Going Concern	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The accompanying consolidated financial statements for the three months ended September 30, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As at September 30, 2023 and June 30, 2023, the Company has shown historical losses and has an accumulated deficit of ($ 41,792,947 41,811,849 174,703 3,491,681 If the Company is unable to raise additional adequate capital, it could be forced to cease operations. Management believes that the Company’s capital requirements will depend on many factors including the success of the Company’s development efforts and its efforts to raise capital. Management also believes the Company needs to raise additional capital for working capital purposes. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to implement its business plan or that any assumptions relating to its business plan will prove accurate. These factors raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Inventory, Prepaid Inventory, a

Inventory, Prepaid Inventory, and Prepaid Expenses	3 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventory, Prepaid Inventory, and Prepaid Expenses	Note 4 – Inventory, Prepaid Inventory, and Prepaid Expenses The Company maintains some inventory in its warehouse and purchases some of its inventory overseas. Inventories, except for stock in transit, are stated at lower of cost and net realizable value. Stock in transit is valued at cost comprising invoice value plus other charges thereon. Net realizable value is the estimated selling price in ordinary course of business less estimated costs of completion and selling expenses. The quantity of inventory may vary from time to time depending on the delivery schedule of overseas shipments. As of September 30, 2023 and June 30, 2023, the Company had $ 8,555 8,555 28,140 7,242

Property and Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment The Company has $20,000 in furnishings, $19,689 in office computers and equipment, and capitalized software development costs of $45,900 which are fully depreciated. On August 30, 2021, the Company purchased its dealer portal for $50,000 for internal use, amortized over 60 months. On September 26, 2022, the Company purchased used furniture for $ 9,442 36 As of September 30, 2023 and June 30, 2023, the Company recorded $ 35,402 and $ 38,689 in net Property and Equipment, respectively: Schedule of property, plant and equipment September 30, June 30, 2023 2023 Furniture $ 20,000 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer portal 50,000 50,000 Furniture 9,443 9,443 Property, plant, and equipment 145,032 145,032 Less accumulated depreciation (109,630 ) (106,343 ) Net property, plant, and equipment $ 35,402 $ 38,689

Accounts payable and accrued ex

Accounts payable and accrued expenses and liabilities	3 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accounts payable and accrued expenses and liabilities	Note 6 – Accounts payable and accrued expenses and liabilities The Company recorded accounts payable of $ 186,417 162,936 Accrued expenses and other current liabilities are expenses that have been incurred but not yet paid, and mainly include legal fees, audit fees and other professional fees as well as accrued interest in connection with the credit line and notes payable. The Company recorded $ 494,764 517,067

Notes Payable and Note payable-

Notes Payable and Note payable-other	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Notes Payable and Note payable-other	Note 7 – Notes Payable and Note payable-other Notes payable consists of notes payable from our subsidiary, notes payable-other, convertible notes payable, notes payable for stock purchases under Reg A, short term notes payable, and notes payable-BOAPIN portal, as follows: Schedule of short term notes payable September 30, June 30, 2023 2023 Notes from subsidiary $ 158,333 $ 158,333 Notes payable - Reg A deposits 140,000 140,000 Short term bridge loan 100,000 100,000 Total notes payable $ 398,333 $ 398,333 Notes Payable - subsidiary The Company has various loans and credit lines outstanding. The credit line carries an interest rate of 6.24 9.24 10.90 Schedule of notes payable September 30, June 30, 2023 2023 Wells Fargo Loan $ 8,770 $ 8,770 On Deck Loan 139,569 139,569 Prosper Loans 9,994 9,994 $ 158,333 $ 158,333 Short term bridge loan - COHEN On July 31, 2020, the Company secured a $ 500,000 12 12 On August 19, 2021, the Company repaid $ 300,000 100,000 At September 30, 2023 and June 30, 2023, the Company recorded a short term note payable of $ 100,000 3,000 3,000 91,677 88,677 Note payable – stock purchases under Reg A At September 30, 2023 and June 30, 2023, the Company has recorded $ 140,000 140,000 2,700 2,700 25,807 23,107 Note Payable – Other In November, 2016, the Company secured a $ 50,000 4 1,000,000 During the three months ended September 30, 2023 and September 30, 2022, the Company recorded interest expense of $ 500 500 13,782 13,282 Convertible note payable – BENZA, D2CF On March 1, 2016 and March 3, 2016, the Company closed a private placement of debt and received an aggregate of $ 612,500 13,750 660,000 On July 21, 2023, the Company entered into settlement agreements with the principals of the company. In the Nevada Lawsuit (see Note 10), the Company agreed to settle for $345,000, with $145,000 paid upon signing and $200,000 due within 6 months. The Settlement Agreement allows for an increased payment of $600,000 if the Second Nevada Settlement Payment isn’t made within six months. In the New York Lawsuit (see Note 10), the Company will pay $80,000, with $10,000 due upon execution of the Settlement. Payments received by the Company will be applied first to the Second New York Payment. On July 26, 2023 the company paid $145,000 to Benza and $10,000 to GQR Consultant as per the settlement agreement (see Note 12). As of September 30, 2023 and June 30, 2023, the Company reported $ 518,750 673,750 Convertible Note – Leonite Capital, LLC On December 5, 2022, the Company received $ 250,000 1,000,000 62,500 March 5, 2024 8,789 270,635 246,148 The Company will begin making nine equal amortization payments of $ 34,722 commencing in the month of July 2023. The Company is required to issue 15,000,000 commitment shares valued at $ 78,000 to Leonite of which $ 28,064 was charged to common stock to be issued. In addition, the Company also paid Leonite $ 10,000 for legal fees incurred by Leonite related to this transaction. The commitment shares and the legal fees have been recorded as deferred debt issuance costs totaling $ 59,936 . The Company amortized $ 11,987 of the deferred debt issuance costs during the three months ended September 30, 2023, and the Company also amortized $ 12,500 of the original issue discount during the three months ended September 30, 2023. The Leonite Convertible Note bears annual interest at the greater of 10 % or the Prime Rate plus three percent (3%). The Leonite Convertible Note is convertible into shares of the Company’s common stock at a conversion price equal to $ 0.007 per share with anti-dilution features. Credit line – MediPendant New York Inc. On September 30, 2014, the subsidiary received a line of credit with Medi Pendant New York, Inc. (“MNY). Under the original terms of the line of credit agreement, the Company was able to borrow up to $ 300,000 6.5 September 30, 2017 500,000 200,000 25,653 8,436 397,500 As of September 30, 2023 and June 30, 2023, the balance due on the line of credit was $ 0 397,500 Debt settlement – On Deck, Susquehanna, MCA Cure In 2019, our subsidiary engaged MCA CURE to negotiate settlements with two creditors: On Deck and Susquehanna Salt, noted in the table above. The Company ceased paying the loan payments and paid to MCA Cure $ 43,875 47,000 90,875 0 0 139,569 139,569 0 0

Shareholders_ Deficit

Shareholders’ Deficit	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Shareholders’ Deficit	Note 10 – Shareholders’ Deficit Preferred Stock: The Company is currently authorized to issue 25,000,000 0.0001 Series A Convertible Preferred Stock 0.0001 Series B Convertible Preferred Stock 0.0001 Series C Convertible Preferred Stock 0.0001 The Company issued 6,700,003 shares for the BOAPIN asset purchase; these shares were issued on September 1, 2020. As of September 30, 2023 and June 30, 2023, 6,838,889 shares of Series C Convertible Preferred Stock were issued and outstanding, respectively. Series D Convertible Preferred Stock : 0.0001 Series E Convertible Preferred Stock : 0.0001 As of September 30, 2023 and June 30, 2023, 4,000,000 Common Stock The Company is currently authorized to issue 3,000,000,000 0.0001 During the three months ended September 30, 2023, · the Company has issued 100,000,000 99,000 · the Company issued 138,000,000 During the three months ended September 30, 2023, the Company also recorded shares to be issued of 1,958,333 1,954 During the three months ended September 30, 2023, the Company received proceeds totaling $ 114,000 115,000,000 99,000 100,000,000 15,000 15,000,000 As of September 30, 2023 and June 30, 2023, the Company has 1,804,255,108 1,566,255,108

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions Note payable – BOAPIN purchase In August 2020, and effective as of June 30, 2020, the Company purchased the BOAPIN portal, including all software, licensing, and ownership rights from Hypersoft Ventures, Inc., a related party through common ownership, for $800,200, which includes six million seven hundred thousand three (6,700,003) shares of Series C Convertible Preferred stock, valued at $375,200 or $0.056 per share, based on the conversion of one share of Series C Preferred stock for 10 shares of common stock and the stock price on the date of the transaction, and a note payable for $425,000, bearing eight percent (8%) interest with no prepayment or delinquency clauses. As of September 30, 2023 and June 30, 2023, the Company has recorded a Note payable-BOAPIN of $ 170,000 170,000 3,428 3,428 66,443 52,853 Related party debt, net From time to time, the Company received funds from related parties for day-to-day operations. These are short-term loans which bear no interest, and the Company expects to repay these loans by the end of the fiscal year following the year in which the short-term loan was made. The following table reflects the composition of the related party debt, net balance at September 30, 2023 and June 30, 2023. Schedule of related party transactions September 30, June 30, 2023 2023 Related parties – subsidiary $ 177,320 $ 177,320 Accrued salaries, bonus, fees 890,275 621,812 Total loans from related parties, net $ 1,067,595 $ 799,132

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 12 – Commitments and contingencies Legal Matters From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. 1) Legal Proceedings Involving Aqualaro Corp On October 24, 2022, Aqualaro Corp. filed a lawsuit against the Company and its transfer agent in the Supreme Court of the State of New York, County of New York. Aqualaro sought monetary damages and an injunction to transfer 56 2) Settlement Agreements on July 21, 2023 The Company entered into a Settlement Agreement related to two litigations: - Benza Pharma, LLC, et al. v. Wearable Health Solutions, Inc., et al. in Clark County Nevada. - GRQ Consultants, Inc. v. Wearable Health Solutions Inc. in the Supreme Court of the State of New York. In the Nevada Lawsuit, the Company agreed to settle for $345,000, with $ 145,000 paid upon signing and $200,000 due within 6 months. The Settlement Agreement allows for an increased payment of $600,000 if the Second Nevada Settlement Payment isn’t made within six months. In the New York Lawsuit, the Company will pay $80,000, with $10,000 due upon execution of the Settlement. Payments received by the Company will be applied first to the Second New York Payment. 3) Medical Alarm Concepts LLC v. MCA Cure, LLC The Company sought the return of payments for non-performance, attorney fees, and court costs. An initial settlement was reached where MCA Cure would pay $10,000 upfront and $6,500 monthly until the debt was paid off in 2023. The defendants breached the settlement agreement, leading to a reopened case. A judgment of $148,875.00, including punitive damages for fraud, was entered against all three defendants on August 25th. Pre-judgment interest of $1,066.60 and costs were also awarded to the plaintiffs. Other than the aforementioned, we are not presently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Commitments and Contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

Office_Warehouse lease

Office/Warehouse lease	3 Months Ended
	Sep. 30, 2023
Officewarehouse Lease
Office/Warehouse lease	Note 13 – Office/Warehouse lease In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating, (1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates most real estate specific lease provisions, and (3) aligns many of the underlying lessor model principles with those in the new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. For public companies, the new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 2020. The Company maintains its corporate office at 2901 W. Coast Highway, Suite 200, Newport Beach, CA 92663. The Company currently pays $175 a month for its office space and the term is month-to-month. The Company’s subsidiary maintained a warehouse office in Pennsylvania to facilitate inventory arrival and product shipment. The three-year lease at $1,100 per month expired on September 30, 2021, and was renewed for 12 months at $1,300 per month beginning October 1, 2021 and expiring on September 30, 2022. The subsidiary subsequently entered into a month-to-month arrangement with this office warehouse and then terminated the arrangement and vacated the facility as of December 31, 2022. The Company entered into a new three-year lease agreement on September 9, 2022 for new warehouse space located in Mequon, Wisconsin. The monthly rent for this new warehouse space is currently $1,325 per month for the first twelve months of the lease agreement. Expenditures for the three months ending September 30, 2023 and 2022 are as follows: Schedule lease cost Three Months Ended 2023 2022 Rent Expenses $ 4,080 $ 5,410 The Company leased a fulfilment center in the U.S., which was classified as an operating lease which subsequently expired on September 30, 2022. The Company determines if an arrangement qualifies as a lease at the lease inception. Operating lease liabilities are recorded based on the present value of the future lease payments over the lease term, assessed as of the commencement date. The Company’s real estate leases, which are for a fulfilment center, generally have a lease term between 3 5 The Company’s lease agreements generally do not specify an implicit borrowing rate, and as such, the Company utilizes its incremental borrowing rate by lease term, in order to calculate the present value of the future lease payments. The discount rate represents a risk-adjusted rate on a secured basis, and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term. The Company’s lease agreement for its warehouse space located in King of Prussia, Pennsylvania expired on September 30, 2022. The Company has terminated the month-to-month arrangement and has vacated the warehouse located in King of Prussia, Pennsylvania as of December 31, 2022. As a result, the Company entered into a new three-year lease agreement on September 9, 2022 for new warehouse space located in Mequon, Wisconsin. The monthly rent which commenced in September 2022 is $1,325 per month and increases approximately 3% annually thereafter. The discount rate used was determined based on the available data as of the lease commencement date. The Right-of-use (“ROU”) asset value added as a result of this new lease agreement was $ 43,058 Certain of the Company’s lease agreements, primarily related to real estate, include options for the Company to either renew (extend) or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between 1 and 3 years. Renewal options are reviewed at lease commencement to determine if such options are reasonably certain of being exercised, which could impact the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several factors, including but not limited to, significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, or specific characteristics unique to the particular lease that would make it reasonably certain that the Company would exercise such option. In most cases, the Company has concluded that renewal and early termination options are not reasonably certain of being exercised by the Company (and thus not included in the Company’s ROU asset and lease liability) unless there is an economic, financial or business reason to do so. The following summarizes (i) the future minimum undiscounted lease payments under non-cancellable lease for each of the next four years and thereafter, incorporating the practical expedient to account for lease and non-lease components as a single lease component for our existing real estate leases, (ii) a reconciliation of the undiscounted lease payments to the present value of the lease liabilities recognized, and (iii) the lease-related account balances on the Company’s consolidated balance sheet, as of September 30, 2023: Schedule of future lease payments Fiscal Year Ending June 30, 2024 $ 12,240 2025 16,670 July & August 2025 2,790 Total future minimum lease payments 31,700 Less imputed interest (2,540 ) Total present value of future minimum lease payments $ 29,160 Schedule of balance sheet related leases As of September 30, 2023 Operating lease right-of-use assets $ 28,740 Accrued lease liability 14,443 Long-term lease liability 14,717 $ 29,160 As of September 30, 2023 Weighted Average Remaining Lease Term 1.92 Weighted Average Discount Rate 8.44

Other income - settlement

Other income - settlement	3 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Other income - settlement	Note 14 – Other income - settlement Settlement In 2019, the Company engaged MCA Cure to negotiate settlements with two note holders, and paid MCA Cure a total of $97,625. In 2020, the Company discovered MCA Cure had not performed when bank accounts were levied for $33,705 and $18,705, being subsequently refunded, and engaged an attorney to recover funds. Currently the Company has a settlement agreement in place with Susquehanna Salt Loan and has hired an attorney to recover funds and damages from MCA Cure. In February 2022, a settlement was reached with MCA Cure for fees and attorney costs of $ 105,125 For the three months ended September 30, 2023 and 2022, the Company recorded $ 0 19,500

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events On November 3, 2023, the Company entered into a Promissory Note Agreement (the “Promissory Note”) with its president Peter Pizzino (“Noteholder”), pursuant to which the Company issued to the Noteholder, on November 3, 2023, Secured Note in an aggregate principal amount of $279,940 (the “Notes”), consisting of gross proceeds of loans of $279,940, that were made in cash by Noteholder to the Company over the past year used for operations, which Note shall not be convertible into the Company’s common stock, par value $0.0001 per share. The Note accrues interest at the rate of 3% per annum and matures on October 7, 2024. Interest on the Note is payable in cash. Upon the occurrence of an event of default, interest accrues at 15% per annum. The Note contains customary default provisions, including provisions for potential acceleration, and covenants, including negative covenants regarding additional indebtedness and dividends. The Company may only prepay the Note with the prior written consent of the respective Noteholder thereof. On November 8, 2023, Mr. Harrysen Mittler resigned from the capacity of CEO and as a Director for the Company. Mr. Peter Pizzino, our current President and Director will take over as the Company’s CEO. The Company evaluated events that have occurred after the balance sheet date but before the financial statements are issued and determined that there are no additional material events that are required to be disclosed.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable 13,820 379 23,705 23,705
Software Development for internal use	Software Development for internal use 50,000 5
Concentration of Credit Risk	Concentration of Credit Risk
Recognition of Revenues	Recognition of Revenues Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company recognizes revenue when it is realized or realizable and earned. For hardware sales, the Company recognizes revenues at a point in time when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues over the term of the service contract and when the services are rendered. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues, and records the balance of revenues as they become current. Schedule of revenues Three Months Ended 2023 2022 Revenue Hardware revenue $ 25,755 $ 26,876 Service Revenue 116,657 189,584 Total Revenue $ 142,412 $ 216,460 Deferred revenues at September 30, 2023 and June 30, 2023 was $ 132,417 103,412
Deferred Taxes	Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2023, 2022, and 2021 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed.
Fair value of financial instruments	Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards.
Research and Development	Research and Development 15,200 2,180
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share - Schedule of anti-dilutive shares September 30, Shares Outstanding Dilution 2023 2022 Series A convertible preferred stock 688 1 share A: 2 shares 1,376 1,376 Series B convertible preferred stock 9,938 1 share B: 2 shares 19,876 19,876 Series C convertible preferred stock 6,838,889 1 share C: 10 shares 68,388,890 68,388,890 Series D convertible preferred stock 425,000 1 share D: 10 shares 4,250,000 4,250,000 Series E convertible preferred stock 4,000,000 1 share E: 100 shares 400,000,000 400,000,000 Common stock to be Issued Leonite Convertible notes 15,000,000 1:1 15,000,000 – Stock subscription liability 24,950,000 1:1 24,950,000 – Others 8,775,832 1:1 8,775,832 76,610,000 Total potentially dilutive shares 521,385,974 549,270,142 Reconciliation of earnings per share Three Months ended 2023 2022 Numerator: Net Income (loss) $ 18,902 $ (748,767 ) Denominator: Weighted average common shares outstanding - basic 1,648,325,760 1,517,790,978 Weighted average common shares outstanding - diluted 2,169,711,734 1,517,790,978 Net income (loss) per share - basic $ 0.00 $ (0.00 ) Net income (loss) per share - diluted $ 0.00 $ (0.00 ) The Company has recognized income for this quarter, as a result, the basic and diluted share bases will not be presented as the same. For the three month periods ended September 30, 2023 and 2022, the Company recognized income of $0.00 and incurred losses of ($0.00) per basic share, respectively. For the three month periods ended September 30, 2023 and 2022, the Company recognized income of $0.00 and incurred losses ($0.00) per diluted share, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of revenues	Schedule of revenues Three Months Ended 2023 2022 Revenue Hardware revenue $ 25,755 $ 26,876 Service Revenue 116,657 189,584 Total Revenue $ 142,412 $ 216,460
Schedule of anti-dilutive shares	Schedule of anti-dilutive shares September 30, Shares Outstanding Dilution 2023 2022 Series A convertible preferred stock 688 1 share A: 2 shares 1,376 1,376 Series B convertible preferred stock 9,938 1 share B: 2 shares 19,876 19,876 Series C convertible preferred stock 6,838,889 1 share C: 10 shares 68,388,890 68,388,890 Series D convertible preferred stock 425,000 1 share D: 10 shares 4,250,000 4,250,000 Series E convertible preferred stock 4,000,000 1 share E: 100 shares 400,000,000 400,000,000 Common stock to be Issued Leonite Convertible notes 15,000,000 1:1 15,000,000 – Stock subscription liability 24,950,000 1:1 24,950,000 – Others 8,775,832 1:1 8,775,832 76,610,000 Total potentially dilutive shares 521,385,974 549,270,142
Reconciliation of earnings per share	Reconciliation of earnings per share Three Months ended 2023 2022 Numerator: Net Income (loss) $ 18,902 $ (748,767 ) Denominator: Weighted average common shares outstanding - basic 1,648,325,760 1,517,790,978 Weighted average common shares outstanding - diluted 2,169,711,734 1,517,790,978 Net income (loss) per share - basic $ 0.00 $ (0.00 ) Net income (loss) per share - diluted $ 0.00 $ (0.00 )

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Schedule of property, plant and equipment September 30, June 30, 2023 2023 Furniture $ 20,000 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer portal 50,000 50,000 Furniture 9,443 9,443 Property, plant, and equipment 145,032 145,032 Less accumulated depreciation (109,630 ) (106,343 ) Net property, plant, and equipment $ 35,402 $ 38,689

Notes Payable and Note payabl_2

Notes Payable and Note payable-other (Tables)	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of short term notes payable	Schedule of short term notes payable September 30, June 30, 2023 2023 Notes from subsidiary $ 158,333 $ 158,333 Notes payable - Reg A deposits 140,000 140,000 Short term bridge loan 100,000 100,000 Total notes payable $ 398,333 $ 398,333
Schedule of notes payable	Schedule of notes payable September 30, June 30, 2023 2023 Wells Fargo Loan $ 8,770 $ 8,770 On Deck Loan 139,569 139,569 Prosper Loans 9,994 9,994 $ 158,333 $ 158,333

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Schedule of related party transactions	Schedule of related party transactions September 30, June 30, 2023 2023 Related parties – subsidiary $ 177,320 $ 177,320 Accrued salaries, bonus, fees 890,275 621,812 Total loans from related parties, net $ 1,067,595 $ 799,132

Office_Warehouse lease (Tables)

Office/Warehouse lease (Tables)	3 Months Ended
	Sep. 30, 2023
Officewarehouse Lease
Schedule lease cost	Schedule lease cost Three Months Ended 2023 2022 Rent Expenses $ 4,080 $ 5,410
Schedule of future lease payments	Schedule of future lease payments Fiscal Year Ending June 30, 2024 $ 12,240 2025 16,670 July & August 2025 2,790 Total future minimum lease payments 31,700 Less imputed interest (2,540 ) Total present value of future minimum lease payments $ 29,160
Schedule of balance sheet related leases	Schedule of balance sheet related leases As of September 30, 2023 Operating lease right-of-use assets $ 28,740 Accrued lease liability 14,443 Long-term lease liability 14,717 $ 29,160 As of September 30, 2023 Weighted Average Remaining Lease Term 1.92 Weighted Average Discount Rate 8.44

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Schedule of Revenues) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Product Information [Line Items]
Revenues	$ 142,412	$ 216,460
Hardware Revenue [Member]
Product Information [Line Items]
Revenues	25,755	26,876
Service Revenue [Member]
Product Information [Line Items]
Revenues	$ 116,657	$ 189,584

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details - Antidilutive information) - shares	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
AntiDilutive Shares	521,385,974	549,270,142
Series A Convertible Preferred Stock [Member]
AntiDilutive Shares	1,376	1,376
Series B Convertible Preferred Stock [Member]
AntiDilutive Shares	19,876	19,876
Series C Convertible Preferred Stock [Member]
AntiDilutive Shares	68,388,890	68,388,890
Series D Convertible Preferred Stock [Member]
AntiDilutive Shares	4,250,000	4,250,000
Series E Convertible Preferred Stock [Member]
AntiDilutive Shares	400,000,000	400,000,000
Leonite Convertible Notes [Member]
AntiDilutive Shares	15,000,000	0
Stock Subscription Liability [Member]
AntiDilutive Shares	24,950,000	0
Others [Member]
AntiDilutive Shares	8,775,832	76,610,000
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	688
Series A Convertible [Member]
Dilution	1 share A: 2 shares
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	9,938
Series B Convertible [Member]
Dilution	1 share B: 2 shares
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	6,838,889
Series C Convertible [Member]
Dilution	1 share C: 10 shares
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	425,000
Series D Convertible [Member]
Dilution	1 share D: 10 shares
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	4,000,000
Series E Convertible [Member]
Dilution	1 share E: 100 shares
Leonite Convertible Notes [Member]
Preferred Stock, Shares Outstanding	15,000,000
Stock Subscription Liability [Member]
Preferred Stock, Shares Outstanding	24,950,000
Others [Member]
Preferred Stock, Shares Outstanding	8,775,832

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details - Reconciliation of earnings per share) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Accounting Policies [Abstract]
Net Income (loss)	$ 18,902	$ (748,767)
Weighted average common shares outstanding - basic	1,648,325,760	1,517,790,978
Weighted average common shares outstanding - diluted	2,169,711,734	1,517,790,978
Net income (loss) per share - basic	$ 0	$ 0
Net income (loss) per share - diluted	$ 0	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended
	Aug. 30, 2021	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Accounts receivable, net		$ 13,820		$ 379
Allowance for doubtful accounts		23,705		23,705
Deferred revenue		132,417		$ 103,412
Research and Development Expense		$ 15,200	$ 2,180
Software Development [Member]
Finite-Lived Intangible Assets [Line Items]
Purchase of dealer portal	$ 50,000
Depreciated years	5 years

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 41,792,947		$ 41,811,849
Net cash used in operating activities	174,703	$ 561,112
Working capital	$ 3,491,681

Inventory, Prepaid Inventory,_2

Inventory, Prepaid Inventory, and Prepaid Expenses (Details Narrative) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory, net	$ 8,555	$ 8,555
Prepaid inventories	$ 28,140	$ 7,242

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 145,032	$ 145,032
Less accumulated depreciation	(109,630)	(106,343)
Net property, plant, and equipment	35,402	38,689
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	20,000	20,000
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	19,689	19,689
Software Development [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	45,900	45,900
Dealer Portal [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	50,000	50,000
Office Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 9,443	$ 9,443

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	Sep. 26, 2022	Sep. 30, 2023	Jun. 30, 2023
Property, Plant and Equipment, Net		$ 35,402	$ 38,689
Used Furniture [Member]
Purchase furniture	$ 9,442
Purchase furniture			36 months

Accounts payable and accrued _2

Accounts payable and accrued expenses and liabilities (Details Narrative) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Payables and Accruals [Abstract]
Accounts payable	$ 186,417	$ 162,936
Accrued expenses and other current liabilities	$ 494,764	$ 517,067

Notes Payable and Note payabl_3

Notes Payable and Note payable-other (Details - Schedule of short term notes) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Debt Disclosure [Abstract]
Notes from subsidiary	$ 158,333	$ 158,333
Notes payable - Reg A deposits	140,000	140,000
Short term bridge loan	100,000	100,000
Total notes payable	$ 398,333	$ 398,333

Notes Payable and Note payabl_4

Notes Payable and Note payable-other (Details - Notes payable) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Debt Instrument [Line Items]
Notes Payable	$ 158,333	$ 158,333
Wells Fargo Loan [Member]
Debt Instrument [Line Items]
Notes Payable	8,770	8,770
On Deck Loan [Member]
Debt Instrument [Line Items]
Notes Payable	139,569	139,569
Prosper Loans [Member]
Debt Instrument [Line Items]
Notes Payable	$ 9,994	$ 9,994

Notes Payable and Note payabl_5

Notes Payable and Note payable-other (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Dec. 05, 2022

Aug. 19, 2021

Jul. 31, 2020

Jan. 31, 2015

Sep. 30, 2014

Sep. 30, 2023

Sep. 30, 2022

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2023

Jun. 30, 2022

Sep. 30, 2020

Nov. 30, 2016

Jun. 30, 2016

Mar. 03, 2016

Mar. 01, 2016

Jun. 30, 2015

Debt Instrument [Line Items]

Rate of interest

6.24%

Principle amount repaid

$ 300,000

Repayment of debt

$ 100,000

Short term notes payable

$ 100,000

$ 100,000

Interest and accrued interest liability

3,000

$ 3,000

Accrued interest payable

91,677

88,677

Interest Payable

66,443

$ 52,853

Loan from related party

140,000

140,000

Amortized deferred debt issuance costs

11,987

172,585

Borrowed amount

$ 300,000

Accrued Interest

$ 25,653

$ 8,436

Gain on debt extinguishment

397,500

0

Line of credit

0

397,500

Notes payable

158,333

158,333

MCA Cure [Member]

Debt Instrument [Line Items]

Loan payments

$ 47,000

$ 43,875

Reserve fund

$ 90,875

Medi Pendant New York Inc [Member]

Debt Instrument [Line Items]

Stock for services, shares

200,000

Medi Pendant [Member]

Debt Instrument [Line Items]

Rate of interest

6.50%

Rate of interest

$ 5,000

Medi Pendant [Member] | Medi Pendant New York Inc [Member]

Debt Instrument [Line Items]

Maturity date

Sep. 30, 2017

Notes Payable, Other Payables [Member]

Debt Instrument [Line Items]

Interest expense

500

500

Interest Payable

13,782

$ 13,282

B2CF [Member]

Debt Instrument [Line Items]

Convertible notes

$ 13,750

$ 13,750

BENZA [Member]

Debt Instrument [Line Items]

Convertible notes

660,000

660,000

BENZA and D2CF [Member]

Debt Instrument [Line Items]

Convertible notes

$ 518,750

673,750

Leonite Convertible Note [Member]

Debt Instrument [Line Items]

Interest rate

10%

Interest expense

$ 8,789

Proceeds from convertible debt

$ 250,000

Convertible note face value

1,000,000

Original issue discount

$ 62,500

Maturity date

Mar. 05, 2024

Amortization payments

$ 34,722

Number of shares issued other

15,000,000

Number of value issued other

$ 78,000

Common stocks to be issued

28,064

Legal fees

10,000

Deferred debt issuance costs

59,936

Amortized deferred debt issuance costs

11,987

Amortized original issue discount

$ 12,500

Conversion price

$ 0.007

Leonite Payable [Member]

Debt Instrument [Line Items]

Convertible notes

$ 270,635

246,148

MCA Cure [Member]

Debt Instrument [Line Items]

Notes payable

0

0

On Deck Loan [Member]

Debt Instrument [Line Items]

Notes payable

139,569

139,569

Susquehanna Salt Loan [Member]

Debt Instrument [Line Items]

Notes payable

0

0

Chief Executive Officer [Member]

Debt Instrument [Line Items]

Acquisition of convertible notes payable

1,000,000

Chief Executive Officer [Member]

Debt Instrument [Line Items]

Loan from related party

$ 50,000

Interest rate

4%

Leonite [Member]

Debt Instrument [Line Items]

Gain on debt extinguishment

397,500

Regulation A Filing [Member] | Two Unaffiliated Investors [Member]

Debt Instrument [Line Items]

Accepted stock payment

140,000

140,000

Interest expense

2,700

$ 2,700

Interest Payable

$ 25,807

$ 23,107

Private Placement [Member]

Debt Instrument [Line Items]

Aggregate amount

$ 612,500

$ 612,500

COHEN [Member]

Debt Instrument [Line Items]

Short term bridge loan

$ 500,000

Interest rate

12%

Accrue interest

12%

Minimum [Member]

Debt Instrument [Line Items]

Interest rate

9.24%

Maximum [Member]

Debt Instrument [Line Items]

Interest rate

10.90%

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized	3,000,000,000		3,000,000,000
Common stock, par value	$ 0.0001		$ 0.0001
Proceeds from Issuance of Common Stock	$ 114,000	$ 634,500
Common stock, shares issued	1,804,255,108		1,566,255,108
Common stock, shares outstanding	1,804,255,108		1,566,255,108
Officers [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares to be issued for compensation, shares	1,958,333
Shares to be issued for compensation, value	$ 1,954
Regulation A Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares sold for cash, shares	100,000,000
Proceeds from Issuance of Common Stock	$ 99,000
Subscriptions [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares sold for cash, shares	138,000,000
Stock To Be Issued [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares sold for cash, shares	115,000,000
Accepted stock payment	$ 114,000
Stock To Be Issued [Member] | Subscription Agreements 1 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares sold for cash, shares	100,000,000
Accepted stock payment	$ 99,000
Stock To Be Issued [Member] | Subscription Agreements 2 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares sold for cash, shares	15,000,000
Accepted stock payment	$ 15,000
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized	100,000		100,000
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding	688		688
Preferred stock, shares issued	688		688
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized	62,500		62,500
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding	9,938		9,938
Preferred stock, shares issued	9,938		9,938
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized	6,944,445		6,944,445
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding	6,838,889		6,838,889
Preferred stock, shares issued	6,838,889		6,838,889
Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized	500,000		500,000
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding	425,000		425,000
Preferred stock, shares issued	425,000		425,000
Series E Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized	4,000,000		4,000,000
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding	4,000,000		4,000,000
Preferred stock, shares issued	4,000,000		4,000,000
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized	25,000,000
Preferred stock, par value	$ 0.0001

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Related Party Transactions [Abstract]
Related parties – subsidiary	$ 177,320	$ 177,320
Accrued salaries, bonus, fees	890,275	621,812
Total loans from related parties, net	$ 1,067,595	$ 799,132

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Related Party Transaction [Line Items]
Debt expensed	$ 3,428	$ 3,428
Accrued interest		$ 66,443		$ 52,853
Boapin [Member]
Related Party Transaction [Line Items]
Note payable	$ 170,000		$ 170,000

Commitments and contingencies (

Commitments and contingencies (Details Narrative) shares in Millions	Oct. 24, 2022 shares
Commitments and Contingencies Disclosure [Abstract]
Monetary damages and injunction to transfer shares	56

Office_Warehouse lease (Details

Office/Warehouse lease (Details) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Officewarehouse Lease
Rent Expenses	$ 4,080	$ 5,410

Office_Warehouse lease (Detai_2

Office/Warehouse lease (Details 1)	Sep. 30, 2023 USD ($)
Officewarehouse Lease
2024	$ 12,240
2025	16,670
July & August 2025	2,790
Total future minimum lease payments	31,700
Less imputed interest	(2,540)
Total present value of future minimum lease payments	$ 29,160

Office_Warehouse lease (Detai_3

Office/Warehouse lease (Details 2) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Officewarehouse Lease
Operating lease right-of-use assets	$ 28,740	$ 32,157
Accrued lease liability	14,443
Long-term lease liability	14,717	$ 18,468
Operating lease liability	$ 29,160
Weighted Average Remaining Lease Term	1 year 11 months 1 day
Weighted Average Discount Rate	8.44%

Office_Warehouse lease (Detai_4

Office/Warehouse lease (Details Narrative) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Right of use asset	$ 28,740	$ 32,157
New Lease Agreement [Member]
Right of use asset	$ 43,058
Minimum [Member]
Lease term	3 years
Maximum [Member]
Lease term	5 years

Other income - settlement (Deta

Other income - settlement (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Feb. 28, 2022
Other Income and Expenses [Abstract]
Attorney costs			$ 105,125
Settlement income	$ 0	$ 19,500